Idorsia successfully completes an upsized offering of shares funding the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION,…
Hibiki Path Advisors has Requested the Board of Directors of Tomoe Corporation (1921) for a Complete Overhaul of the Medium-Term Management Plan and Establishment of a Special Committee
TOKYO--(BUSINESS WIRE)--Hibiki Path Advisors (“Hibiki” or “We”) is a Singapore-based investment management…
Orano: Beginning of a New Phase for the Nurlikum Mining Joint Venture in Uzbekistan
PARIS--(BUSINESS WIRE)--Regulatory News: In September 2025, the state-owned enterprise Navoiyuran (Uzbekistan), the…
Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases
Hinge Bio to receive $10 million upfront and is eligible to receive…
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
September 29, 2025 19:30 ET | Source: Nxera Pharma Tokyo, Japan and…
Xinhua Silk Road: “Wuliangye Day” glistens at Expo 2025 Osaka
BEIJING, Sept. 24, 2025 /PRNewswire/ -- When the "Wuliangye Day" event opened…
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY (Piflufolastat F 18) in Japan
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) --…
Japan Ground Self-Defense Force Adopts MEDIROM MOTHER Labs REMONY for Advanced Health Monitoring and Heatstroke Safety
TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ:…
Hyundai Motor Group Champions Hydrogen Innovation at Osaka Energy Ministerial Meetings
Hyundai Motor Group participates in the 1st Ministerial Meeting on Sustainable Fuels…
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being…